<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1611211332
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2004
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TOTAM 1GM IV\IM INJECTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CEFOTAXIME
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        g
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Parenteral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        powder for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        29.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Al Hikma Pharmaceutical Portugal Lda" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Al Hikma Pharmaceutical Portugal Lda
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DD01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cefotaxime is an antibiotic, i.e. a medicine which is used for the treatment of bacterial infections of:</p><ul><li>The lungs (pneumonia)</li><li>The skin and soft tissue</li><li>The urinary tract</li><li>The genitals (including gonorrhoea)</li><li>The heart valves (endocarditis)</li><li>The membranes covering the brain (meningitis)</li><li>The abdomen</li><li>The blood (so called &lsquo;bacteraemia&rsquo;)</li></ul><p>Furthermore, cefotaxime is used to treat the Lyme disease (borreliosis, an infection primarily caused by tick bites, e.g. relapsing fever).</p><p>Cefotaxime can also be used before and during surgery in order to prevent possible infections</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You must not be given Totam if you:</strong></p><ul><li>Are allergic (hypersensitive) to cefotaxime or to any cephalosporin antibiotics or any of the other ingredients of this medicine (listed in section 6)</li><li>Have ever had a severe allergic (hypersensitive) reaction to any other type of beta-lactam antibiotic (penicillins, monobactams and carbapenems)</li></ul><p>Totam is sometimes mixed with another medicine called lidocaine. In this case do not have this injection if:</p><ul><li>You are allergic to lidocaine or other local anaesthetics</li><li>Your child is younger than 30 months</li><li>You have heart disease, problems with your heartbeat or severe heart failure</li></ul><p>Do not have this medicine if any of the above applies to you. If you are not sure, talk to your doctor or nurse before you are given Totam.</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor, pharmacist or nurse before you are given Totam:</p><ul><li>If you have allergic reactions. If you have had any allergic reaction to other antibiotics such as penicillin, you may also be allergic to Totam. If an allergic reaction occurs, treatment must be stopped</li><li>If you suffer from severe, persistent diarrhoea during or after treatment with Totam. In this case contact your doctor immediately. Do not take any anti-diarrhoea medicine without consulting your doctor</li><li>If you have a widespread rash with blisters and peeling skin. (These may be signs of Stevens-Johnson syndrome or toxic epidermal necrolysis)</li><li>If you have kidney problems</li><li>If you experience e.g. impairment of consciousness, abnormal movements and cramps after being given this medicine.</li><li>If you are on a low salt diet. Then the sodium content of this product must be taken into account.</li></ul><p>If any of these apply to you, your doctor may want to change your treatment or give you special advice.</p><p>If you are given this medicine over a longer period, your doctor will take additional care and check your blood for possible changes. Also the overgrowth of bacteria that are unsusceptible to cefotaxime must be examined regularly in this case.</p><p><strong>Other medicines and </strong><strong>Totam</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines you buy without a prescription, and herbal medicines.</p><p>This is because Totam can affect the way some other medicines work. Also some medicines can affect the way Totam works.</p><p>In particular, check with your doctor if you are taking any of the following:</p><ul><li>Aminoglycoside antibiotics &ndash; including gentamicin, streptomicin, neomycin, kanamycin, amikacin or tobramycin</li><li>Water tablets (diuretics) such as furosemide, etacrynic acid</li><li>Probenecid &ndash; used for gout</li></ul><p><strong>Tests</strong></p><p>If you require any tests (such as blood, urine or diagnostic) while taking this medicine, please make sure your doctor knows that you are taking Totam.</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before you are given this medicine.</p><p><strong>Driving and using machines </strong></p><p>You may start to move abnormally, suffer from sudden involuntary muscle contractions, dizziness or feel less alert.</p><p>If this happens, do not drive or use any tools or machines.</p><p><strong>Totam contains sodium </strong></p><p>Totam contains sodium. Each vial of Totam 1000 mg Powder for Solution for Injection/Infusion contains 2.20 mmol (50.50 mg) sodium (main component of cooking/table salt). This is equivalent to 2.52% of the recommended maximum daily dietary intake of sodium for an adult</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><em>Administration</em></strong></p><p>Totam is always administered by healthcare personnel. This medicine is first dissolved in sterile water or another suitable solution. The solution may be given as an injection or through a tube (infusion) into a vein, for certain infections it may also be injected into a muscle.</p><p><strong><em>Dosage</em></strong></p><p><strong>Adults and adolescents over 12 years</strong></p><p>You usually receive 2000 to 6000 mg Totam daily. The daily dose should be divided in two single doses every 12 hours.</p><p>The dosage may be varied according to the severity of your infection and your condition:</p><ul><li>Common infections in presence (or suspicion) of sensitive bacteria: 1000 mg every 12 hours (i.e. total daily dose of 2000 mg).</li><li>Infections in presence (or suspicion) of several sensitive or moderately sensitive bacteria: 1000&ndash;2000 mg every 12 hours (i.e. total daily dose of 2000&ndash;4000 mg).</li><li>Severe infections or for infections that cannot be localised: 2000&ndash;3000 mg as a single dose every 6 to 8 hours (i.e. a maximum daily dose of 12000 mg).</li></ul><p><strong>Newborns (0&ndash;28 days), infants and children up to 12 years of age</strong></p><p>The dosage is dependent on the severity of the infection.</p><p>The usual dosage for newborns, infants and children is 50 to 100 to 150 mg cefotaxime per kg body weight per day, divided into 2 to 4 single doses (i.e. every 12 to 6 hours).</p><p>For very severe or life-threatening infections up to 200 mg cefotaxime per kg body weight per day, divided into 2 to 4 single doses, may be required. The doctor will take the differences in maturation of the kidneys and their function into account, especially in newborns from 0&ndash;7 days.</p><p><strong>Premature infants</strong></p><p>The recommended dosage is 50 mg per kg body weight per day divided into 2 to 4 doses (every 12 to 6 hours). This maximum dose should not be exceeded due to the not yet fully matured kidneys.</p><p><strong>Elderly</strong></p><p>Provided that your kidney and liver function is normal, no dosage adjustment is required.</p><p><strong>People with kidney and/or liver problems</strong></p><p>If you have problems with your kidneys and/or liver, you may be given a lower dose. You may need to have blood tests to check that you are getting the dose you need. Your doctor will decide on the dose.</p><p><strong>Other special recommendations</strong></p><p><em>Gonorrhoea</em></p><p>You will receive a single injection of 500 mg&ndash;1000 mg Totam as an injection into a muscle or a vein for treatment of gonorrhoea.</p><p><em>Bacterial meningitis</em></p><p>Adults receive a daily dose of 9000 to 12000 mg Totam divided into equal doses every 6 to 8 hours.</p><p>Children receive 150 to 200 mg per kg body weight divided into equal doses every 6 to 8 hours.</p><p>Newborns: 0-7 days old babies receive 50 mg per kg body weight every 12 hours, 7&ndash;28 days old infants every 8 hours.</p><p><em>Prevention of infections (perioperative prophylaxis)</em></p><p>You may be given between 1000 mg and 2000 mg Totam before an operation for the prevention of possible infections. If the operation lasts longer than 90 minutes, you may be given an additional dose preventively.</p><p><em>Infections inside the abdomen</em></p><p>You should be given a combination of Totam and an antibiotic acting against &lsquo;anaerobic&rsquo; bacteria.</p><p><strong><em>Treatment duration</em></strong></p><p>Your treatment duration depends on the severity of your infection as well as on your recovery from your illness.</p><p>You will usually continue to be given the medicine for at least 2 to 3 days after you have started to recover from your illness. Treatment over at least 10 days is necessary in infections caused by the bacterium Streptococcus pyogenes.</p><p><strong>If you are given more Totam than you should</strong></p><p>Tell your doctor or nurse if you think that you have been given too much Totam.</p><p><strong>If you forget to use Totam</strong></p><p>Please contact your doctor immediately. A double dose must not be given to make up for a forgotten dose. A forgotten dose should be given only if the time until the next regular dose is long enough.</p><p><strong>If you stop using </strong><strong>Totam</strong></p><p>Low dosage, irregular administration or stopping treatment too early can compromise the outcome of the treatment or lead to a relapse, whose treatment is more difficult. Please follow the instructions of your doctor.</p><p>If you have any further questions on the use of this medicine ask your doctor, pharmacist or nurse</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>You must contact your doctor immediately if you notice any of the following:</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people)</strong></p><ul><li>Increased tendency to bleed or bruise more easily caused by a fall in the number of blood platelets (thrombocytopenia), fever, sore throat or mouth ulcers due to infections caused by a low level of white blood cells (leucopenia) or high level of a specific type of white blood cells (eosinophilia)</li></ul><p><strong>Not known: frequency cannot be estimated from the available data</strong></p><ul><li>Inflammation of the bowels, called colitis (or antibiotic associated colitis), causing severe long-lasting watery or bloody diarrhoea with stomach cramps and fever</li><li>Serious blood problems, including changes in the numbers of some white blood cells (which may cause frequent infections, fever, severe chills, sore throat, or mouth ulcers)</li><li>Damage to red blood cells (causing tiredness, being short of breath or looking pale)</li><li>Severe allergic reactions with symptoms such as swelling of the lips, tongue, face and neck, sudden difficulty in breathing, speaking and swallowing;</li><li>Headache, dizziness, convulsions (fits) (these may be symptoms of a brain disorder called encephalopathy)</li><li>Changes in heart beat (rhythm or rate), after a very quick injection into a vein</li><li>Yellow skin and eyes, loss of appetite, light-coloured urine caused by inflammation of the liver</li><li>Skin rash, which may blister, and looks like small targets (central dark spot surrounded by a paler area, with a dark ring around the edge)</li><li>A widespread rash with blisters and peeling skin. (These may be signs of Stevens-Johnson syndrome or toxic epidermal necrolysis)</li><li>Increased or reduced urine output, or traces of blood in your urine, sometimes with swollen limbs and/or flank pain caused by kidney problems</li><li>For intramuscular injection: combination with lidocaine can cause systemic reactions</li></ul><p><strong><em>Other possible side effects:</em></strong></p><p><strong>Very common: may affect more than 1 in 10 people</strong></p><ul><li>Intramuscular injection may be painful<strong>&nbsp;</strong></li></ul><p><strong>Uncommon: may affect up to 1 in 100 people</strong></p><ul><li>People being treated for infections with bacteria called spirochetes often show symptoms like fever and shivering which are described as &lsquo;Herxheimer reaction&rsquo; and indicate the effectiveness of the therapy.</li><li>Changes in the results of blood tests that check how the liver and kidneys are working</li><li>Fever</li><li>Allergic reactions such as skin rash (nettle rash), itchy skin</li><li>Painful swelling and inflammation where the injection is given into a vein</li><li>Soft stools or diarrhoea</li><li>Convulsions</li></ul><p><strong>Not known: frequency cannot be estimated from the available data</strong></p><ul><li>Feeling sick (nausea) and being sick (vomiting)</li><li>Pain in your stomach (abdomen)</li></ul><p>Your doctor may want to perform tests during your treatment to measure any changes</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 25&deg;C.</p><p>Store in the original package in order to protect from light.</p><p><strong>After reconstitution:</strong></p><p>Chemical and physical in-use stability has been demonstrated for 24 hours at 2&ndash;8&deg;C after reconstitution with water for injection and 1% lidocaine.</p><p>From a microbiological point of view, unless the method of reconstitution precludes the risk of microbial contamination, the product should be used immediately.</p><p>If not used immediately, in-use storage times and conditions are the responsibility of user.</p><p><strong>After reconstitution and dilution:</strong></p><p>Chemical and physical in-use stability for the diluted medicinal product has been demonstrated for 24 hours at 2&ndash;8&deg;C.</p><p>From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2&ndash;8&deg;C, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice description of the visible signs of deterioration.</p><p>Do not throw away any medicines via waste water or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is cefotaxime sodium.</p><p>Each vial of Totam 1000 mg Powder for Solution for Injection/Infusion contains cefotaxime sodium equivalent to 1000 mg cefotaxime.</p><p>There are no other ingredients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Totam 1000 mg Powder for Solution for Injection/Infusion is a white to slightly yellowish powder in clear glass colorless vials sealed with light grey colour caps.

After reconstitution, clear solution, no visible residue, not significantly less clear than an equal amount of the diluent.

Pack size: 1 Vial. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder </strong></p><p>Jazeera Pharmaceutical Industries</p><p>Al-Kharj Road</p><p>P.O. Box 106229</p><p>Riyadh 11666, Saudi Arabia</p><p>Tel: + (966-11) 8107023, + (966-11) 2142472</p><p>Fax: + (966-11) 2078170</p><p>e-mail: SAPV@hikma.com</p><p><strong>Manufacturer</strong></p><p>Hikma Farmaceutica (Portugal), S.A.</p><p>Estrada do Rio Da M&oacute;,</p><p>n.&deg;8, 8A e 8B, Ferven&ccedil;a</p><p>2705-906 Terrugem</p><p>Sintra, Portugal</p><p>Tel: + (351-2) 19608410</p><p>Fax: + (351-2) 19615102<br />&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly see details below. By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 01/2024; version number SA1.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">سيفوتاكسيم هو مضاد حيوي، أي دواء يُستخدَم لعلاج العدوى البكتيرية التي تصيب:</p><ul dir="rtl"><li>الرئتين (الالتهاب الرئوي)</li><li>الجلد والأنسجة الرخوة</li><li>المسالك البولية</li><li>الأعضاء التناسلية (بما في ذلك السيلان)</li><li>صمامات القلب (التهاب الشغاف)</li><li>الأغشية التي تغطي المخ (التهاب السحايا)</li><li>البطن</li><li>الدم (الذي يُطلق عليه &quot;تجرثم الدم&quot;)</li></ul><p dir="RTL">وعلاوةً على ذلك، يُستخدَم سيفوتاكسيم لعلاج داء لايم (داء بوريليا، وهي عدوى سببها الأساسي هو لدغات القراد، على سبيل المثال، الحمّى الناكسة).</p><p dir="RTL">يمكن أيضًا استخدام سيفوتاكسيم قبل وأثناء الجراحة من أجل منع العدوى المحتملة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عدم إعطاؤك توتام إذا:</strong></p><ul dir="rtl"><li>كنت تعاني من حساسية (فرط تحسس) لسيفوتاكسيم أو أي من مضادات سيفالوسبورين الحيوية أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6)</li><li>حدث لديك رد فعل تحسسي شديد (فرط تحسس) لأي مضادات بيتا-لاكتام الحيوية الأخرى (البنسلين والمونوباكتام والكاربابينيم)</li></ul><p dir="RTL">يتم في بعض الأحيان خلط توتام مع دواء آخر يُطلق عليه ليدوكايين. في هذه الحالة لا تستخدم هذا الحقن إذا:</p><ul dir="rtl"><li>كنت تعاني من حساسية لليدوكايين أو التخديرات الموضعية الأخرى</li><li>كان طفلك أصغر من 30 شهرًا</li><li>كان لديك أحد أمراض القلب أو مشاكل في ضربات القلب أو فشل قلبي شديد</li></ul><p dir="RTL">لا تستخدم هذا الدواء إذا انطبق عليك أي مما سبق. إذا لم تكن متأكدًا، تحدث مع طبيبك أو الممرض قبل إعطائك توتام.</p><p dir="RTL"><strong>الاحتياطات والتحذيرات </strong></p><p dir="RTL">تحدث مع طبيبك، الصيدلي أو الممرض قبل إعطائك توتام:</p><ul dir="rtl"><li>إذا حدث لديك ردود فعل تحسسية. إذا كان قد حدث لديك أي رد فعل تحسسي لأي مضاد حيوي آخر مثل البنسلين، فقد تكون لديك أيضًا حساسية من توتام. إذا حدث رد فعل تحسسي، يجب إيقاف العلاج</li><li>إذا كنت تعاني من إسهال شديد أو مستمر أثناء العلاج بتوتام أو بعده. في هذه الحالة اتصل بالطبيب على الفور. لا تستخدم أي دواء مضاد للإسهال دون استشارة طبيبك</li><li>إذا كنت تعاني من طفح منتشر مع بثور وتقشر الجلد. (قد تكون هذه علامات لمتلازمة ستِيفنس جونسُون أو تقشر الأنسجة المتموتة البشروية السمي)</li><li>إذا كنت تعاني من مشاكل في الكلى</li><li>إذا تعرضت على سبيل المثال لضعف الوعي، حركات غير طبيعية وشد عضلي بعد إعطاؤك هذا الدواء.</li><li>إذا كنت تتبع نظامًا غذائيًا منخفض الملح. فيجب أخذ محتوى الصوديوم لهذا المستحضر في الاعتبار.</li></ul><p dir="RTL">إذا كان أي مما سبق ينطبق عليك، فقد يحتاج طبيبك إلى تغيير علاجك أو إعطائك نصيحة خاصة.</p><p dir="RTL">إذا تم إعطاؤك هذا الدواء على فترة أطول، سيقوم طبيبك برعاية إضافية ويفحص دمك للتأكد من عدم وجود تغيرات محتملة. كما يجب فحص فرط نمو البكتيريا الغير حساسة لسيفوتاكسيم بانتظام في هذه الحالة.</p><p dir="RTL"><strong>الأدوية الأخرى و</strong><strong>توتام</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخرًا أو قد تتناول أي أدوية أخرى، يتضمن ذلك الأدوية التي تقوم بشرائها بدون وصفة طبية، والأدوية العشبية.</p><p dir="RTL">ويرجع السبب في هذا إلى أن توتام يؤثر على آلية عمل بعض الأدوية الأخرى. وتؤثر بعض الأدوية أيضًا على آلية عمل توتام.</p><p dir="RTL">على وجه الخصوص، تحقق من طبيبك إذا كنت تتناول أي مما يلي:</p><ul dir="rtl"><li>مضادات أمينوغليكوزيد الحيوية - التي تشمل جنتاميسين، ستربتوميسين، نيوميسين، كاناميسين، أميكاسين أو توبراميسين</li><li>أقراص الماء (مدرات البول) مثل فوروسيميد، حمض الإيثاكرينيك</li><li>&nbsp;بروبينسيد - يُستخدَم لمرض النقرس</li></ul><p dir="RTL"><strong>الفحوصات</strong></p><p dir="RTL">إذا كنت تتطلب أي فحوصات (مثل الدم، البول أو التشخيصية) أثناء استخدام هذا الدواء، يُرجى التأكد من أن طبيبك يعرف أنك تستخدم سيفوتاكسيم.</p><p dir="RTL"><strong>الحمل والرضاعة </strong></p><p dir="RTL">إذا كنت حاملاً أو مرضعًا، تعتقدين بأنك حامل أو تخططين لذلك، اطلبي النصيحة من طبيبك قبل أن يتم اعطاؤك هذا الدواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">قد تبدأ في التحرك بشكل غير طبيعي، تعاني من انقباضات عضلية لا إرادية مفاجئة، دوخة أو تشعر أنك أقل يقظة.</p><p dir="RTL">إذا حدث هذا، لا تقود أو تستخدم أي أدوات أو آلات.</p><p dir="RTL"><strong>يحتوي</strong> <strong>توتام</strong><strong> على الصوديوم </strong></p><p dir="RTL">يحتوي توتام على الصوديوم. تحتوي كل زجاجة من توتام 1000 ملغم مسحوق للحل للحقن/للتسريب على 2.20 ملمول (50.50 ملغم) صوديوم (المكون الرئيسي للطهي/ملح الطعام).<strong> </strong>هذا يكافئ 2.52% من الكمية الغذائية اليومية<strong> </strong>القصوى الموصى بتناولها من الصوديوم للبالغين<strong>.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong><em>الإعطاء</em></strong></p><p dir="RTL">يتم إعطاء توتام دائمًا من قبل مسؤولي الرعاية الصحية. يتم إذابة هذا الدواء أولاً في ماء معقم أو محلول مناسب آخر. يمكن إعطاء المحلول كحقنة أو من خلال أنبوب (تسريب) في الوريد، لبعض حالات معينة من العدوى يمكن حقنه كذلك في العضل.</p><p dir="RTL"><strong><em>الجرعة</em></strong></p><p dir="RTL"><strong>البالغون والمراهقون الذين تزيد أعمارهم عن 12 سنة</strong></p><p dir="RTL">عادةً ما تحصل على 2000 إلى 6000 ملغم من توتام يوميًا. يجب تقسيم الجرعة اليومية إلى جرعتين منفردتين كل 12 ساعة.</p><p dir="RTL">قد تختلف الجرعة وفقًا لشدة العدوى الخاصة بك وحالتك:</p><ul dir="rtl"><li>حالات العدوى الشائعة عند وجود (أو الاشتباه في وجود) البكتريا الحساسة: 1000 ملغم &nbsp;كل 12 ساعة (أي جرعة يومية إجمالية 2000 ملغم).</li><li>حالات العدوى عند وجود (أو الاشتباه في وجود) العديد من البكتريا الحساسة أو المتوسطة الحساسية: 1000-2000 ملغم كل 12 ساعة (أي جرعة يومية إجمالية 2000-4000 ملغم).</li><li>حالات العدوى الحادة أو حالات العدوى التي لا يمكن تحديد موضعها: 2000-3000 ملغم كجرعة منفردة كل 6 إلى 8 ساعات (أي جرعة يومية قصوى 12000 ملغم).</li></ul><p dir="RTL"><strong>حديثي الولادة (0 - 28 يومًا)، الرضع والأطفال حتى &nbsp;12 عامًا</strong></p><p dir="RTL">تعتمد الجرعة على شدة العدوى. الجرعة المعتادة لحديثي الولادة والرضع والأطفال هي من 50 إلى 100 إلى 150 ملغم سيفوتاكسيم لكل كغم من وزن الجسم لكل يوم، مقسمة إلى 2 إلى 4 جرعات منفردة (أي كل 12 إلى 6 ساعات).</p><p dir="RTL">لحالات العدوى الشديدة للغاية أو المهددة للحياة، قد يكون من المطلوب إعطاء لغاية 200 ملغم سيفوتاكسيم لكل كغم من وزن الجسم لكل يوم، مقسمة إلى 2 إلى 4 جرعات منفردة. سيأخذ الطبيب الاختلافات في نضج الكلى ووظيفتها في الاعتبار، وبخاصة في حالات حديثي الولادة من 0 - 7 أيام.<strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال الخدج </strong></p><p dir="RTL">الجرعة الموصى بها هي 50 ملغم لكل كغم من وزن الجسم لكل اليوم مقسمة إلى 2 إلى 4 جرعات (كل 12 إلى 6 ساعات). لا ينبغي تجاوز هذه الجرعة القصوى بسبب الكلى التي لم تنضج بالكامل بعد.</p><p dir="RTL"><strong>كبار السن</strong></p><p dir="RTL">شريطة أن تكون وظائف الكلى والكبد طبيعية، لا يلزم تعديل الجرعة.<em>&nbsp;</em></p><p dir="RTL"><strong>الأشخاص الذين يعانون من مشاكل في الكلى و/أو الكبد</strong></p><p dir="RTL">إذا كنت تعاني من مشاكل في الكلى و/أو الكبد، يمكن أن يتم إعطاؤك جرعة أقل. قد تحتاج إلى إجراء فحوصات الدم للتحقق من أنك تحصل على الجرعة التي تحتاجها. سيحدد طبيبك الجرعة.</p><p dir="RTL"><strong>توصيات خاصة أخرى</strong></p><p dir="RTL"><em>السيلان</em></p><p dir="RTL">ستحصل على حقنة منفردة 500 ملغم &ndash;1000 ملغم من توتام كحقنة في العضل أو الوريد لعلاج السيلان.</p><p dir="RTL"><em>التهاب السحايا البكتيري</em></p><p dir="RTL">البالغون يحصلون على جرعة يومية من 9000 إلى 12000 ملغم من توتام مقسمة إلى جرعات متساوية كل 6 إلى 8 ساعات.<em>&nbsp;</em></p><p dir="RTL">الأطفال يحصلون على 150 إلى 200 ملغم لكل كغم من وزن الجسم مقسمة إلى جرعات متساوية كل 6 إلى 8 ساعات.</p><p dir="RTL">حديثي الولادة: يحصل الأطفال الذين تتراوح أعمارهم من 0-7 أيام على 50 ملغم لكل كغم من وزن الجسم كل 12 ساعة، ويحصل الأطفال الذين تتراوح أعمارهم من 7-28 يومًا على الجرعة كل 8 ساعات.</p><p dir="RTL"><em>الوقاية من حالات العدوى (الوقاية خلال الفترة المحيطة بالجراحة)</em></p><p dir="RTL">قد يتم إعطاؤك بين 1000 ملغم و 2000 ملغم توتام قبل الخضوع لعملية جراحية للوقاية من حالات العدوى المحتملة. إذا كانت العملية تستمر لفترة أطول من 90 دقيقة، فقد يتم إعطاؤك جرعة وقائية إضافية.</p><p dir="RTL"><em>حالات العدوى داخل البطن</em></p><p dir="RTL">يجب أن تحصل على مزيج من توتام ومضاد حيوي يعمل ضد البكتيريا &quot;اللاهوائية&quot;.</p><p dir="RTL"><strong><em>مدة العلاج</em></strong></p><p dir="RTL">تعتمد مدة علاجك على شدة العدوى الخاصة بك وكذلك على شفائك من مرضك.</p><p dir="RTL">عادةً ما تستمر في الحصول على الدواء لمدة 2 إلى 3 أيام على الأقل بعد أن تبدأ في التعافي من مرضك. يلزم العلاج لمدة 10 أيام على الأقل في حالات العدوى الناجمة عن العقديات العقدية المقيحة البكتيرية.</p><p dir="RTL"><strong>إذا تم إعطاؤك توتام أكثر من اللازم</strong></p><p dir="RTL">أخبر طبيبك أو الممرض إذا كنت تعتقد أنه قد تم إعطاؤك جرعة زائدة من توتام.</p><p dir="RTL"><strong>إذا نسيت استخدام توتام</strong></p><p dir="RTL">يُرجى الاتصال بطبيبك على الفور. يجب عدم إعطاء جرعة مضاعفة لتعويض الجرعة المنسية. يجب إعطاء الجرعة المنسية فقط إذا كان الوقت حتى الجرعة العادية التالية طويلاً بما يكفي.</p><p dir="RTL"><strong>إذا توقفت عن استخدام </strong><strong>توتام</strong></p><p dir="RTL">الجرعة المنخفضة، الإعطاء غير المنتظم أو إيقاف العلاج في وقت مبكر جدًا يمكن أن يضر بنتيجة العلاج أو يؤدي إلى انتكاس، والذي يكون علاجه أكثر صعوبة. يُرجى اتباع إرشادات طبيبك.</p><p dir="RTL">إذا كان لديك أي أسئلة إضافية حول استخدام هذا الدواء، اسأل الطبيب، الصيدلي أو الممرض</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثارًا جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL">يجب عليك الاتصال بالطبيب على الفور إذا لاحظت أي مما يلي:</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة (قد تؤثر فيما يصل إلى شخص</strong><strong> </strong><strong>من بين كل 100 شخص)</strong></p><ul dir="rtl"><li>زيادة النزعة إلى النزيف أو الإصابة بالتكدم بسهولة أكبر بسبب انخفاض عدد الصفائح الدموية (نقص الصفيحات)، الحمى، التهاب الحلق أو قرح فموية بسبب العدوى الناجمة عن انخفاض مستوى خلايا الدم البيضاء (قلة الكريات البيض) أو ارتفاع مستوى نوع معين من خلايا الدم البيضاء (كثرة اليوزينيات)</li></ul><p dir="RTL"><strong>غير معروفة: لا يمكن تقدير التكرار من</strong><strong> </strong><strong>البيانات المتاحة</strong></p><ul dir="rtl"><li>التهاب الأمعاء، الذي يُسمى التهاب القولون (أو التهاب القولون المرافق للمضادات الحيوية)، والذي يسبب إسهالاً مائيًا شديد يستمر طويلاً أو إسهالاً دمويًا مع تشنجات في المعدة وحمى</li><li>مشاكل خطيرة في الدم، تشمل التغيرات في أعداد بعض خلايا الدم البيضاء (والتي قد تسبب عدوى متكررة، حمى، قشعريرة شديدة، التهاب الحلق أو قرحً فموية)</li><li>&nbsp;تلف لخلايا الدم الحمراء (والذي يسبب الإرهاق، ضيق في التنفس أو المظهر الشاحب)</li><li>ردود فعل تحسسية شديدة مع أعراض مثل تورم الشفاه، اللسان، الوجه والرقبة، صعوبة مفاجئة في التنفس، التحدث والبلع؛</li><li>صداع، دوخة، تشنّجات (نوبات) (وقد تكون هذه أعراض لاضطراب دماغي يسمى الاعتلال الدماغي)</li><li>تغيرات في ضربات القلب (النظم أو المعدل)، بعد إعطاء حقنة سريعة للغاية في وريد</li><li>تلون الجلد والعينين باللون الأصفر، فقدان الشهية، بول فاتح اللون بسبب التهاب الكبد</li><li>طفح جلدي، الذي قد يتبثر، ويبدو شكلها مثل الأهداف الصغيرة (بقع داكنة مركزية محاطة بمنطقة أكثر شحوبًا، مع حلقة داكنة حول الأطراف)</li><li>طفح منتشر مع بثور وتقشر الجلد. (قد تكون هذه علامات لمتلازمة ستِيفنس جونسُون أو تقشر الأنسجة المتموتة البشروية السمي)</li><li>زيادة أو انخفاض النتاج البولي، أو آثار الدم في البول، وفي بعض الأحيان يرافقه تورم الأطراف و/أو ألم الخاصرة الناجم عن مشاكل في الكلى</li><li>للحقن العضلي: بالاجتماع مع ليدوكائين يمكن أن يسبب ردود فعل جهازية</li></ul><p dir="RTL"><strong><em>آثار جانبية أخرى محتملة:</em></strong></p><p dir="RTL"><strong>شائعة جدًا: قد تؤثر في أكثر من شخص من بين كل </strong>10<strong> أشخاص</strong></p><ul dir="rtl"><li>قد يكون الحقن العضلي مؤلمًا</li></ul><p dir="RTL"><strong>غير شائعة: قد تؤثر فيما يصل إلى شخص من بين كل </strong>100<strong> شخص</strong></p><ul dir="rtl"><li>الأشخاص الذين يتم علاجهم من حالات العدوى بالبكتريا التي يطلق عليها اللولبية غالبًا ما تظهر لديهم أعراض مثل الحمى والارتجاف والتي توصف بأنها &quot;تفاعل هيركسهيمر&quot; وتشير إلى فعالية العلاج.</li><li>تغيرات في نتائج فحوصات الدم التي تتحقق من كيفية عمل الكبد والكلى</li><li>الحمى</li><li>ردود فعل تحسسية مثل الطفح الجلدي (الطفح القراصي)، حكة في الجلد</li><li>تورم والتهاب مؤلم في موضع الحقن الوريدي</li><li>براز لين أو إسهال</li><li>تشنجات</li></ul><p dir="RTL"><strong>غير معروفة: لا يمكن تقدير التكرار من البيانات المتاحة</strong></p><ul dir="rtl"><li>الشعور بالمرض (الغثيان) والمرض (التقيؤ)</li><li>ألم في المعدة (البطن)</li></ul><p dir="RTL">قد يحتاج طبيبك إلى إجراء فحوصات أثناء العلاج لقياس أية تغيرات</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 25&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الضوء.</p><p dir="RTL"><strong>بعد الحل:</strong></p><p dir="RTL">تم إثبات الاستقرار الكيميائي والفيزيائي أثناء الاستخدام لمدة 24 ساعة عند درجة حرارة 2-8&deg; مئوية بعد الحل بماء معد للحقن و1% ليدوكايين.</p><p dir="RTL">من وجهة نظر ميكروبيولوجية، إذا لم تمنع طريقة الحل خطر التلوث بالميكروبات، يجب استخدام المستحضر على الفور. في حال عدم الاستخدام على الفور، تقع مسؤولية فترات التخزين أثناء الاستخدام وظروف التخزين على المستخدم.</p><p dir="RTL"><strong>بعد </strong><strong>الحل</strong><strong> والتخفيف:</strong></p><p dir="RTL">تم إثبات الاستقرار الكيميائي والفيزيائي أثناء الاستخدام للمستحضر الدوائي المخفف لمدة 24 ساعة عند درجة حرارة 2-8&deg; مئوية.</p><p dir="RTL">من وجهة نظر ميكروبيولوجية، يجب استخدام المستحضر على الفور. في حال عدم الاستخدام على الفور، تقع مسؤولية فترات التخزين أثناء الاستخدام وظروف التخزين قبل الاستخدام على المستخدم وهي في المعتاد لن تزيد عن 24 ساعة عند درجة حرارة 2-8&deg; مئوية، ما لم تتم الحل/التخفيف في ظروف معقمة خاضعة للرقابة وتم التحقق منها.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي سيفوتاكسيم الصوديوم.</p><p dir="RTL">تحتوي كل زجاجة من توتام 1000 ملغم مسحوق للحل للحقن/للتسريب على سيفوتاكسيم صوديوم يكافئ 1000 ملغم سيفوتاكسيم.</p><p dir="RTL">لا توجد مكونات أخرى.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">توتام 1000 ملغم مسحوق للحل للحقن/للتسريب هو مسحوق أبيض مائل إلى الاصفرار في زجاجات شفافة عديمة اللون محكمة الإغلاق بأغطية لونها رمادي فاتح.</p><p dir="RTL">بعد الحل، محلول صافٍ، بدون رواسب مرئية، ليس أقل صفاءً بكثير من كمية مساوية من المادة المخففة.</p><p dir="RTL">حجم العبوة: زجاجة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق </strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية</p><p dir="RTL">طريق الخرج</p><p dir="RTL">صندوق بريد 106229</p><p dir="RTL">الرياض 11666، المملكة العربية السعودية</p><p dir="RTL">هاتف: 8107023 (11-966) +، 2142472 (11-966) +</p><p dir="RTL">فاكس: 2078170 (11-966) +</p><p dir="RTL">البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">شركة أدوية الحكمة (البرتغال)، المساهمة العامة المحدودة</p><p dir="RTL">إسترادا دو ريو دا مو،</p><p dir="RTL">مبنى رقم &deg;8, 8A e 8B، فارفانسا</p><p dir="RTL">906-2705 تيروجيم</p><p dir="RTL">سنترا، البرتغال</p><p dir="RTL">هاتف: 19608410 (2-351) +</p><p dir="RTL">فاكس: 19615102 (2-351) +</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أي آثار جانبية. وذلك يتضمن أي آثار جانبية محتملة لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً، انظر التفاصيل المذكورة أدناه. من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul dir="rtl"><li>المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني:&nbsp; https://ade.sfda.gov.sa</p><ul dir="rtl"><li>دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 2024/01؛ رقم النسخة SA1.0.


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Totam 1000 mg Powder for Solution for Injection/Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains cefotaxime sodium equivalent to 1000 mg cefotaxime.

Excipients with known effect: Sodium.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for Solution for Injection/Infusion.

White to slightly yellowish powder.

After reconstitution, clear solution, no visible residue, not significantly less clear than an equal amount of the diluent.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Totam is indicated in the treatment of the following severe infections when known or thought very likely to be caused by bacteria that are susceptible to cefotaxime (see section 4.4 and 5.1):</p><ul><li>Bacterial pneumonia</li><li>Complicated infections of the urinary tract including pyelonephritis</li><li>Severe skin and soft tissue infections</li><li>Genital infections, including gonorrhoea</li><li>Intra-abdominal infections (such as peritonitis)</li><li>Bacterial meningitis</li><li>Endocarditis</li><li>Borreliosis</li></ul><p>Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.</p><p>Perioperative prophylaxis. For surgical operations with increased risk of infections with anaerobic pathogens, e.g. colorectal surgery, a combination with an appropriate drug with activity against anaerobes is recommended.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p>Totam may be administered by intravenous bolus injection or intravenous infusion or by intramuscular injection after reconstitution of the solution.</p><p>Dosage and mode of administration should be determined by the severity of the infection, susceptibility of the causative organism and the patient&rsquo;s condition. Therapy may be started before the result of microbiological tests are known.</p><p><u>Adults and adolescents over 12 years</u></p><p>Adults and adolescents usually receive 2000 to 6000 mg cefotaxime daily. The daily dose should be divided in two single doses every 12 hours.</p><ul><li>Common infections in presence (or suspicion) of sensitive bacteria: 1000 mg every 12 hours.</li><li>Infections in presence (or suspicion) of several sensitive or moderately sensitive bacteria: 1000 &ndash; 2000 mg every 12 hours.</li><li>Severe infections or for infections that cannot be localised: 2000 &ndash; 3000 mg as a single dose every 6 to 8 hours (maximum daily dose: 12000 mg).</li></ul><p>A combination of cefotaxime and other antibiotics is indicated in severe infections.</p><p><u>Term newborn (0-28 days), infants and children up to 12 years of age</u></p><p>Depending on the severity of the infection: 50 &ndash; 100 &ndash; 150 mg/kg/day, 12 &ndash; 6 hourly.</p><p>In life-threatening situations the daily dose may be raised to 200 mg/kg/day under careful attention of the renal function, especially in the newborn period 0 &ndash; 7 days due to not fully matured kidney function.</p><p><u>Premature infants</u></p><p>The recommended dosage is 50 mg/kg/day divided into 2 to 4 doses (every 12 to 6 hours). This maximum dose should not be exceeded due to the not yet fully matured kidneys.</p><p><u>Elderly</u></p><p>No dosage adjustment is required, provided that the function of the kidneys and the liver is normal.</p><p><u>Other special recommendations</u></p><p><em>Gonorrhoea</em></p><p>For gonorrhoea, a single injection (intramuscularly or intravenously) of 500 mg &ndash; 1000 mg cefotaxime. For complicated infections, consideration should be given to available official guidelines. Syphilis should be excluded before initiating treatment.</p><p><em>Bacterial meningitis</em></p><p>Adults: Daily dose of 9000 &ndash; 12000 mg cefotaxime divided into equal doses every 6 &ndash; 8 hours (3000 mg 3 &ndash; 4 times daily).</p><p>Children: 150 &ndash; 200 mg/kg/day divided into equal doses every 6 &ndash; 8 hours.</p><p>Newborns: 0 &ndash; 7 days: 50 mg/kg every 12 hours, 7 &ndash; 28 days: 50 mg/kg every 8 hours.</p><p><em>Perioperative prophylaxis</em></p><p>1000 &ndash; 2000 mg as single dose as close to start of surgery as possible. In those cases where the operation time exceeds 90 minute an additional dose of prophylactic antibiotic should be given.</p><p><em>Intra-abdominal infections</em></p><p>Intra-abdominal infections should be treated with cefotaxime in combination with other antibiotics with coverage for anaerobic bacteria.</p><p><u>Dosage in renal function impairment</u></p><p>In adult patients with a creatinine clearance of &le; 5 ml/min, the initial dose equal to the recommended usual dose but the maintenance dose should be reduced by half without change in the frequency of dosing. Blood tests to determine the required dose may be carried out.</p><p><u>Dosage in dialysis or peritoneal dialysis</u></p><p>In patients on haemodialysis and peritoneal dialysis an intravenous injection of 500 mg &ndash; 2000 mg, given at the end of each dialysis session and repeated every 24 hours, is sufficient to treat most infections efficaciously.</p><p><strong>Duration of therapy</strong></p><p>The duration of therapy with cefotaxime depends on the clinical condition of the patient and varies according to the bacteriological progress. Administration of cefotaxime should be continued until symptoms have subsided or evidence of bacterial eradication has been obtained. Treatment over at least 10 days is necessary in infections caused by <em>Streptococcus pyogenes</em> (parenteral therapy may be switched to an adequate oral therapy before the end of the 10 days period).</p><p><strong>Method of administration</strong></p><p><u>Intravenous infusion</u></p><p>In order to avoid any risk of infection, the reconstitution of the solution for infusion should be done in close aseptic conditions. Do not postpone the infusion after the reconstitution of the solution.</p><p><em>For short intravenous infusion:</em> Following reconstitution, the solution should be administered over 20 minutes.</p><p><em>For long lasting intravenous infusion:</em> Following reconstitution, the solution should be administered over 50 &ndash; 60 minutes.</p><p><u>Intravenous injection</u></p><p>For intermittent i.v. injections, the solution must be injected over a period of 3 to 5 minutes. During post-marketing surveillance, potentially life-threatening arrhythmia has been reported in a very few patients who received rapid intravenous administration of cefotaxime through a central venous catheter.</p><p><u>Intramuscular injection</u></p><p>The intramuscular method of administration is restricted to exceptional clinical situations (e.g. gonorrhoea). It is not indicated in severe infections and should undergo a risk-benefit assessment. It is recommended that no more than 4 ml are injected unilaterally. If the daily dose exceeds 2000 mg cefotaxime or if cefotaxime is injected more frequently than twice per day, the intravenous route is recommended.</p><p>In case of severe infections, intramuscular injection is not recommended. The solution should be administered by deep intramuscular injection. Solutions with lidocaine must not be administered intravenously. Cefotaxime reconstituted with lidocaine should not be administrated to children in the first year of age. The product information of the chosen lidocaine containing medicinal product must be regarded.</p><p>For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6. Cefotaxime and aminoglycosides should not be mixed in the same syringe or perfusion fluid.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance, to other cephalosporins or any of the excipients listed in section 6.1.
•	Previous, immediate and/or severe hypersensitivity reaction to penicillin or any betalactam antibiotic.

For pharmaceutical forms containing lidocaine:
•	Known history of hypersensitivity to lidocaine or other local anesthetics of the amide type
•	Non-paced heart block
•	Severe heart failure
•	Administration by the intravenous route
•	Infants aged less than 30 months of age
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As with other antibiotics, the use of cefotaxime, especially if prolonged, may result in overgrowth of non-susceptible organisms. Repeated evaluation of the patient&rsquo;s condition is essential. If superinfection occurs during therapy, appropriate measures should be taken.</p><p><strong>Anaphylactic reactions</strong></p><p>Serious, including fatal hypersensitivity reactions have been reported in patients receiving cefotaxime (see sections 4.3 and 4.8).</p><p>If a hypersensitivity reaction occurs, treatment must be stopped.</p><p>The use of cefotaxime is strictly contra-indicated in subjects with a previous history of immediate-type hypersensitivity to cephalosporins.</p><p>Since cross allergy exists between penicillins and cephalosporins, use of the latter should be undertaken with extreme caution in penicillin sensitive subjects.</p><p><strong>Serious bullous reactions</strong></p><p>Cases of serious bullous skin reactions like Stevens-Johnson syndrome or toxic epidermal necrolysis have been reported with cefotaxime (see section 4.8). Patients should be advised to contact their doctor immediately prior to continuing treatment if skin and/or mucosal reactions occur.</p><p><strong>Clostridium difficile associated disease (e.g. pseudomembranous colitis)</strong></p><p>Diarrhea, particularly if severe and/or persistent, occurring during treatment or in the initial weeks following treatment, may be symptomatic of Clostridium difficile associated disease (CDAD). CDAD may range in severity from mild to life threatening, the most severe form of which is pseudo-membranous colitis.</p><p>The diagnosis of this rare but possibly fatal condition can be confirmed by endoscopy and/or histology.</p><p>It is important to consider this diagnosis in patients who present with diarrhea during or subsequent to the administration of cefotaxime.</p><p>If a diagnosis of pseudomembranous colitis is suspected, cefotaxime should be stopped immediately and appropriate specific antibiotic therapy should be started without delay.</p><p>Clostridium difficile associated disease can be favoured by faecal stasis.</p><p>Medicinal products that inhibit peristalsis should not be given.</p><p><strong>Haematological reactions</strong></p><p>Leucopenia, neutropenia and, more rarely, bone marrow failure, pancytopenia, or agranulocytosis may develop during treatment with cefotaxime (see Section 4.8.).</p><p>For treatment courses lasting longer than 7 &ndash; 10 days, the blood white cell count should be monitored and treatment stopped in the event of neutropenia.</p><p>Some cases of eosinophilia and thrombocytopenia, rapidly reversible on stopping treatment, have been reported. Cases of haemolytic anemia have also been reported. (see section 4.8).</p><p><strong>Patients with renal insufficiency</strong></p><p>For patients with impaired renal function, the dosage should be modified according to the creatinine clearance calculated (see section 4.2).</p><p>Caution should be exercised if cefotaxime is administered together with aminoglycosides; probenecid or other nephrotoxic drugs (see section 4.5).</p><p>Renal function must be monitored in these patients, the elderly, and those with preexisting renal impairment.</p><p><strong>Neurotoxicity</strong></p><p>High doses of beta-lactam antibiotics, including cefotaxime, particularly in patients with renal insufficiency, may result in encephalopathy (e.g. impairment of consciousness, abnormal movements and convulsions) (see section 4.8).</p><p>Patients should be advised to contact their doctor immediately prior to continuing treatment if such reactions occur.</p><p>The use of cefotaxime for treatment of endocarditis should be restricted to patients known to have penicillin allergy (not type 1). Cefotaxime should be used incombination with other appropriate antibacterial agents, considering its limited antibacterial spectrum.</p><p><strong>Precautions for administration</strong></p><p>During post-marketing surveillance, potentially life-threatening arrhythmia has been reported in a very few patients who received rapid intravenous administration of cefotaxime through a central venous catheter. The recommended time for injection or infusion should be followed (see section 4.2).</p><p>See section 4.3 for contraindications for formulations containing lidocaine.</p><p><strong>Effects on Laboratory Tests</strong></p><p>As with other cephalosporins a positive Coombs&#39; test has been found in some patients treated with cefotaxime. This phenomenon can interfere with the cross-matching of blood.</p><p>Urinary glucose testing with non-specific reducing agents may yield false positive results. This phenomenon is not seen when a glucose-oxydase specific method is used.</p><p><strong>Totam contains sodium</strong></p><p>Totam contains sodium. Each vial of Totam 1000 mg Powder for Solution for Injection/Infusion contains 2.20 mmol (50.50 mg) sodium (main component of cooking/table salt). This is equivalent to 2.52% of the recommended maximum daily dietary intake of sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Uricosurics</em>:</p><p>Probenecid interferes with the renal tubular transfer of cefotaxime, thereby increasing cefotaxime exposure about 2-fold and reducing renal clearance to about half at therapeutic doses. Due to the large therapeutic index of cefotaxime, no dosage adjustment is needed in patients with normal renal function. Dosage adjustment may be needed in patients with renal impairment (see sections 4.4 and 4.2).</p><p><em>Aminoglycoside antibiotics and diuretics:</em></p><p>As with other cephalosporins, cefotaxime may potentiate the nephrotoxic effects of nephrotoxic drugs such as aminoglycosides or potent diuretics (e.g. furosemide). Renal function must be monitored in these patients (see section 4.4).</p><p><em>Bacteriostatic antibiotics:</em></p><p>Cefotaxime should not be combined with bacteriostatic antibiotics (e.g. tetracyclines, erythromycin and chloramphenicol) because an antagonistic effect is possible.</p><p><em>Interference with Laboratory Tests:</em></p><p>As with other cephalosporins, a positive Coombs&#39; test has been seen in some patients treated with cefotaxime. This phenomenon can interfere with the cross-matching of blood.</p><p>A false positive reaction to glucose may occur with reducing substances (e.g. Fehling&#39;s solution) but not with the use of specific glucose oxidase methods.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Uricosurics</em>:</p><p>Probenecid interferes with the renal tubular transfer of cefotaxime, thereby increasing cefotaxime exposure about 2-fold and reducing renal clearance to about half at therapeutic doses. Due to the large therapeutic index of cefotaxime, no dosage adjustment is needed in patients with normal renal function. Dosage adjustment may be needed in patients with renal impairment (see sections 4.4 and 4.2).</p><p><em>Aminoglycoside antibiotics and diuretics:</em></p><p>As with other cephalosporins, cefotaxime may potentiate the nephrotoxic effects of nephrotoxic drugs such as aminoglycosides or potent diuretics (e.g. furosemide). Renal function must be monitored in these patients (see section 4.4).</p><p><em>Bacteriostatic antibiotics:</em></p><p>Cefotaxime should not be combined with bacteriostatic antibiotics (e.g. tetracyclines, erythromycin and chloramphenicol) because an antagonistic effect is possible.</p><p><em>Interference with Laboratory Tests:</em></p><p>As with other cephalosporins, a positive Coombs&#39; test has been seen in some patients treated with cefotaxime. This phenomenon can interfere with the cross-matching of blood.</p><p>A false positive reaction to glucose may occur with reducing substances (e.g. Fehling&#39;s solution) but not with the use of specific glucose oxidase methods.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no evidence that cefotaxime directly impairs the ability to drive or to operate machines.</p><p>High doses of cefotaxime, particularly in patients with renal insufficiency, may cause encephalopathy (e.g. impairment of consciousness, abnormal movements and convulsions) (see section 4.8).</p><p>In the case of side effects such as dizziness the patient&#39;s ability to concentrate and to react properly may be impaired. In such cases patients should refrain from driving cars and using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:1234px"><tbody><tr><td style="vertical-align:top; width:228px"><p>System organ class</p><p>&nbsp;</p></td><td style="vertical-align:top; width:113px"><p>Very Common</p><p>(&ge;1/10)</p><p>&nbsp;</p></td><td style="vertical-align:top; width:62px"><p>Common (&ge;1/100 to</p><p>&lt;1/10)</p><p>&nbsp;</p></td><td style="vertical-align:top; width:243px"><p>Uncommon (&ge;1/1,000 to</p><p>&lt;1/100)</p><p>&nbsp;</p></td><td style="vertical-align:top; width:218px"><p>Rare (&ge;1/10,0 00 to &lt;1/1,000)</p></td><td style="vertical-align:top"><p>Very rare (&lt;1/10,0</p><p>00)</p><p>&nbsp;</p></td><td style="vertical-align:top; width:278px"><p>Not known (cannot be estimated from available data)*</p></td></tr><tr><td style="vertical-align:top; width:228px"><p>Infections and infestati-ons</p></td><td style="vertical-align:top; width:113px"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:62px"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:243px"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:218px"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:278px"><p>Super-infection (see section 4.4)<strong> </strong></p></td></tr><tr><td style="vertical-align:top; width:228px"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top; width:113px"><p>&nbsp;</p></td><td style="vertical-align:top; width:62px"><p>&nbsp;</p></td><td style="vertical-align:top; width:243px"><p>Leucopenia</p><p>Eosinophilia</p><p>Thrombocytopenia</p></td><td style="vertical-align:top; width:218px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:278px"><p>Bone marrow failure</p><p>Pancytopenia</p><p>Neutropenia</p><p>Agranulo-cytosis (see section 4.4)</p><p>Haemolytic anaemia</p></td></tr><tr><td style="vertical-align:top; width:228px"><p>Immune system disorders</p></td><td style="vertical-align:top; width:113px"><p>&nbsp;</p></td><td style="vertical-align:top; width:62px"><p>&nbsp;</p></td><td style="vertical-align:top; width:243px"><p>Jarisch</p><p>Herxheimer reaction</p></td><td style="vertical-align:top; width:218px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:278px"><p>Anaphylactic reactions</p><p>Angioedema</p><p>Broncho-spasm Anaphylactic shock</p></td></tr><tr><td style="vertical-align:top; width:228px"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:113px"><p>&nbsp;</p></td><td style="vertical-align:top; width:62px"><p>&nbsp;</p></td><td style="vertical-align:top; width:243px"><p>Convul-sions (see section 4.4)</p></td><td style="vertical-align:top; width:218px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:278px"><p>Headache</p><p>Dizziness</p><p>Encephalopa-thy (e.g. impairment of conscious-ness, abnormal movements) (see section 4.4)</p></td></tr><tr><td style="vertical-align:top; width:228px"><p>Cardiac disorders</p></td><td style="vertical-align:top; width:113px"><p>&nbsp;</p></td><td style="vertical-align:top; width:62px"><p>&nbsp;</p></td><td style="vertical-align:top; width:243px"><p>&nbsp;</p></td><td style="vertical-align:top; width:218px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:278px"><p>Arrhythmia following rapid bolus infusion through central venous catheter,</p><p>Palpitations</p></td></tr><tr><td style="vertical-align:top; width:228px"><p>Gastro-intestinal disorders</p></td><td style="vertical-align:top; width:113px"><p>&nbsp;</p></td><td style="vertical-align:top; width:62px"><p>&nbsp;</p></td><td style="vertical-align:top; width:243px"><p>Diarrhea</p></td><td style="vertical-align:top; width:218px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:278px"><p>Nausea</p><p>Vomiting</p><p>Abdominal pain Pseudo- membranous colitis (see section 4.4)</p><p>Candidiasis</p></td></tr><tr><td style="vertical-align:top; width:228px"><p>Hepato-bilary disorders</p></td><td style="vertical-align:top; width:113px"><p>&nbsp;</p></td><td style="vertical-align:top; width:62px"><p>&nbsp;</p></td><td style="vertical-align:top; width:243px"><p>Increase in liver enzymes (ALAT, ASAT,</p></td><td style="vertical-align:top; width:218px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:278px"><p>Hepatitis* (sometimes with jaundice)</p></td></tr><tr><td style="vertical-align:top; width:228px"><p>&nbsp;</p></td><td style="vertical-align:top; width:113px"><p>&nbsp;</p></td><td style="vertical-align:top; width:62px"><p>&nbsp;</p></td><td style="vertical-align:top; width:243px"><p>LDH, Gamma-GT and/or alkaline phosphatase) and/or bilirubin</p></td><td style="vertical-align:top; width:218px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:278px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:228px"><p>Skin ande Sub-cutaneous tissue disorders</p></td><td style="vertical-align:top; width:113px"><p>&nbsp;</p></td><td style="vertical-align:top; width:62px"><p>&nbsp;</p></td><td style="vertical-align:top; width:243px"><p>Rash</p><p>Pruritus</p><p>Urticaria</p></td><td style="vertical-align:top; width:218px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:278px"><p>Erythema multiforme Stevens-Johnson syndrome Toxic epidermal necrolysis (see section 4.4)</p><p>Acute generalized Exanthe-matous</p><p>pustulosis</p><p>(AGEP)</p></td></tr><tr><td style="vertical-align:top; width:228px"><p>Renal and Urinary disorders</p></td><td style="vertical-align:top; width:113px"><p>&nbsp;</p></td><td style="vertical-align:top; width:62px"><p>&nbsp;</p></td><td style="vertical-align:top; width:243px"><p>Decrease in renal function/ increase of creatinine (particu-larly when coprescribed with aminoglycosides)</p></td><td style="vertical-align:top; width:218px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:278px"><p>Acute renal failure (see Section 4.4) Interstititial nephritis</p></td></tr><tr><td style="vertical-align:top; width:228px"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top; width:113px"><p><em>For IM formulations: </em>Pain at the injection site</p></td><td style="vertical-align:top; width:62px"><p>&nbsp;</p></td><td style="vertical-align:top; width:243px"><p>Fever</p><p>Inflam-matory reactions at the injection site, including phlebitis/ thrombo- phlebitis, Malaise,&nbsp;</p><p>Fatigue</p></td><td style="vertical-align:top; width:218px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:278px"><p><em>For IM formulations (since the solvent contains lidocaine)</em>: Systemic reactions to lidocaine</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>Jarisch-Herxheimer reaction</em></p><p>For the treatment of borreliosis (Lyme&rsquo;s Disease), a Jarisch-Herxheimer reaction may develop during the first days of treatment.</p><p>The occurrence of one or more of the following symptoms has been reported after several week&#39;s treatment of borreliosis: skin rash, itching, fever, leucopenia, increase in liver enzymes, difficulty of breathing, joint discomfort.</p><p><em>Hepatobiliary disorders</em></p><p>Increase in liver enzymes (ALAT, ASAT, LDH, gamma-GT and/or alkaline phosphatase) and/or bilirubin have been observed. These laboratory abnormalities may rarely exceed twice the upper limit of the normal range and elicit a pattern of liver injury, usually cholestatic and most often asymptomatic.</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&middot;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp; Other GCC States</p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms of overdose may largely correspond to the profile of side effects.</p><p>There is a risk of reversible encephalopathy in cases of administration of high doses of &szlig;-lactam antibiotics including cefotaxime.</p><p>In case of overdose, cefotaxime must be discontinued, and supportive treatment initiated, which includes measures to accelerate elimination, and symptomatic treatment of adverse reactions (e.g. convulsions).</p><p>No specific antidote exists. Serum levels of cefotaxime can be reduced by haemodialysis or peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Third-generation cephalosporin, ATC code: J01DD01</p><p><strong>Mechanism of action&nbsp; </strong></p><p>The bactericidal activity of cefotaxime results from the inhibition of bacterial cell wall synthesis (during the period of growth) caused by an inhibition of penicillin-binding proteins (PBPs) like transpeptidases.</p><p><strong>Mechanism of resistance </strong></p><p>A resistance to cefotaxime may be caused by following mechanisms:</p><ul><li>Inactivation by beta-lactamases. Cefotaxime can be hydrolysed by certain beta-lactamases, especially by extended-spectrum beta-lactamases (ESBLs) which can be found in strains of <em>Escherichia coli</em> or <em>Klebsiella pneumoniae</em>, or by chromosomal encoded inducible or constitutive beta-lactamases of the AmpC type which can be detected in <em>Enterobacter cloacae</em>. Therefore, infections caused by pathogens with inducible, chromosomal encoded AmpC-beta-lactamases should not be treated with cefotaxime even in case of proven <em>in-vitro</em> susceptibility because of the risk of the selection of mutants with constitutive, derepressed AmpC- beta-lactamases-expression.&nbsp;</li><li>Reduced affinity of PBPs to cefotaxime. The acquired resistance of Pneumococci and other Streptococci is caused by modifications of already existing PBPs as a consequence of a mutation process. In contrast to this concerning the methicillin-(oxacillin-) resistant <em>Staphylococcus</em>, the creation of an additional PBP with reduced affinity to cefotaxime is responsible for resistance.&nbsp;</li><li>Inadequate penetration of cefotaxime through the outer cell membrane of gram-negative bacteria so that the inhibition of the PBPs is insufficient.&nbsp;</li><li>The presence of transport mechanism (efflux pumps) being able to actively transport cefotaxime out of the cell. A complete cross resistance of cefotaxime occurs with ceftriaxone and partially with other penicillins and cephalosporins.</li></ul><p><strong>Breakpoints </strong></p><p>The following minimal inhibitory concentrations were defined for sensitive and resistant germs:&nbsp;</p><p>EUCAST (European Committee on Antimicrobial Susceptibility Testing) breakpoints (2019-01-01):&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td style="vertical-align:top; width:280px"><p>&nbsp;</p></td><td style="vertical-align:top; width:168px"><p><strong>Susceptible </strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:162px"><p><strong>Resistant</strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:280px"><p><em>Enterobacteriaceae</em><em> </em></p></td><td style="vertical-align:top; width:168px"><p>&le; 1 mg/L&nbsp;</p></td><td style="vertical-align:top; width:162px"><p>&gt; 2 mg/L</p></td></tr><tr><td style="vertical-align:top; width:280px"><p><em>Staphylococcus </em><em>spp. <sup>HE</sup></em><em><sup> </sup></em><em>&nbsp;</em></p></td><td style="vertical-align:top; width:168px"><p>Note<sup>1</sup></p></td><td style="vertical-align:top; width:162px"><p>Note<sup>1</sup></p></td></tr><tr><td style="vertical-align:top; width:280px"><p><em>Streptococcus</em> (group A, B, C, G)</p></td><td style="vertical-align:top; width:168px"><p>Note<sup>2</sup></p></td><td style="vertical-align:top; width:162px"><p>Note<sup>2</sup></p></td></tr><tr><td style="vertical-align:top; width:280px"><p><em>Streptococcus pneumoniae</em><em> </em></p></td><td style="vertical-align:top; width:168px"><p>&le; 0.5 mg/L</p></td><td style="vertical-align:top; width:162px"><p>&gt; 2 mg/L</p></td></tr><tr><td style="vertical-align:top; width:280px"><p>Viridans group <em>streptococci </em></p></td><td style="vertical-align:top; width:168px"><p>&le; 0.5 mg/L</p></td><td style="vertical-align:top; width:162px"><p>&gt; 0.5 mg/L&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:280px"><p><em>Haemophilus influenzae</em><em> </em></p></td><td style="vertical-align:top; width:168px"><p>&le; 0.125 mg/L&nbsp;</p></td><td style="vertical-align:top; width:162px"><p>&gt; 0.125 mg/L&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:280px"><p><em>Moraxella catarrhalis </em></p></td><td style="vertical-align:top; width:168px"><p>&le; 1 mg/L</p></td><td style="vertical-align:top; width:162px"><p>&gt; 2 mg/L</p></td></tr><tr><td style="vertical-align:top; width:280px"><p><em>Neisseria gonorrhoea</em><em> </em></p></td><td style="vertical-align:top; width:168px"><p>&le; 0.125 mg/L</p></td><td style="vertical-align:top; width:162px"><p>&gt; 0.125 mg/L</p></td></tr><tr><td style="vertical-align:top; width:280px"><p><em>Neisseria meningitidis<sup>3</sup></em><em> </em></p></td><td style="vertical-align:top; width:168px"><p>&le; 0.125 mg/L</p></td><td style="vertical-align:top; width:162px"><p>&gt; 0.125 mg/L</p></td></tr><tr><td style="vertical-align:top; width:280px"><p><em>Pasteurella multocida </em></p></td><td style="vertical-align:top; width:168px"><p>&le; 0.03 mg/L</p></td><td style="vertical-align:top; width:162px"><p>&gt; 0.03 mg/L</p></td></tr><tr><td style="vertical-align:top; width:280px"><p><em>Kingella kingae </em></p></td><td style="vertical-align:top; width:168px"><p>&le; 0.125 mg/L</p></td><td style="vertical-align:top; width:162px"><p>&gt; 0.125 mg/L</p></td></tr><tr><td style="vertical-align:top; width:280px"><p>PK-PD (Non-species related) breakpoints</p></td><td style="vertical-align:top; width:168px"><p>&le; 1 mg/L</p></td><td style="vertical-align:top; width:162px"><p>&gt; 2 mg/L</p></td></tr></tbody></table><p>HE = high exposition / high dose only for <em>S. aureus</em> (high dose of at least 3 x 2000 mg iv)&nbsp;</p><p>1&nbsp; Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam which do not have breakpoints and should not be used for staphylococcal infections.&nbsp;</p><p>2&nbsp; The susceptibility of <em>streptococcus </em>groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.&nbsp;</p><p>3&nbsp; Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.&nbsp;</p><p><strong>Susceptibility </strong></p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. If the efficacy of cefotaxime is questionable due to the local prevalence of resistance, expert opinion should be sought regarding the choice of therapy. In particular in the case of severe infections or failure of therapy, a microbiological diagnosis including a verification of the germ and its susceptibility should be aspired.&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:384px"><tbody><tr><td style="vertical-align:top; width:381px"><p><strong>COMMONLY SUSCEPTIBLE SPECIES </strong></p></td></tr><tr><td style="vertical-align:top; width:381px"><p><strong><em>Gram-positive aerobe</em></strong><em> </em></p><p><em>Staphylococcus aureus</em> (Methicillin-susceptible)</p><p><em>Streptococcus agalactiae </em></p><p><em>Streptococcus pneumoniae</em> (incl. penicillin-resistant strains)</p><p><em>Streptococcus pyogenes </em></p></td></tr><tr><td style="vertical-align:top; width:381px"><p><strong><em>Gram-negative aerobes</em></strong><em> </em></p><p><em>Borrelia burgdorferi </em></p><p><em>Haemophilus influenzae&nbsp; </em></p><p><em>Moraxella catarrhalis&nbsp; </em></p><p><em>Neisseria gonorrhoea&nbsp; </em></p><p><em>Neisseria meningitides </em></p><p><em>Proteus mirabilis<sup>%</sup></em></p></td></tr><tr><td style="vertical-align:top; width:381px"><p><strong>SPECIES FOR WHICH ACQUIRED RESISTANCE MAY BE A PROBLEM</strong></p></td></tr><tr><td style="vertical-align:top; width:381px"><p><strong><em>Gram-positive aerobes</em></strong></p><p><em>Staphylococcus aureus</em></p><p><em>Staphylococcus epidermidis +</em></p><p><em>Staphylococcus haemolyticus +</em></p><p><em>Staphylococcus hominis +</em></p></td></tr><tr><td style="vertical-align:top; width:381px"><p><strong><em>Gram-negative aerobes</em></strong></p><p><em>Citrobacter freundii</em></p><p><em>Enterobacter aerogenes</em></p><p><em>Enterobacter cloacae</em></p><p><em>Escherichia coli<sup>%</sup></em></p><p><em>Klebsiella oxytoca<sup>%</sup></em></p><p><em>Klebsiella pneumoniae<sup># %</sup></em></p><p><em>Morganella morganii</em></p><p><em>Proteus vulgaris</em></p><p><em>Serratia marcescens</em></p></td></tr><tr><td style="vertical-align:top; width:381px"><p><strong>Anaerobes</strong></p><p><em>Bacteroides fragilis</em></p></td></tr><tr><td style="vertical-align:top; width:381px"><p><strong>INHERENTLY RESISTANT SPECIES</strong></p></td></tr><tr><td style="vertical-align:top; width:381px"><p><strong><em>Gram-positive aerobes</em></strong></p><p><em>Enterococcus spp.</em></p><p><em>Listeria monocytogenes</em></p><p><em>Staphylococcus aureus</em> (methicillin-resistant)</p></td></tr><tr><td style="vertical-align:top; width:381px"><p><strong>Gram-negative aerobes</strong></p><p><em>Acinetobacter spp.</em></p></td></tr><tr><td style="vertical-align:top; width:381px"><p><em>Pseudomonas aeruginosa</em></p><p><em>Stenotrophomonas maltophilia</em></p></td></tr><tr><td style="vertical-align:top; width:381px"><p><strong>Anaerobes</strong></p><p><em>Clostridium difficile</em></p></td></tr><tr><td style="vertical-align:top; width:381px"><p><strong>Others</strong></p><p><em>Chlamydia spp.</em></p><p><em>Chlamydophila spp.</em></p><p><em>Legionella pneumophila</em></p><p><em>Mycoplasma spp.</em></p><p><em>Treponema pallidum</em></p></td></tr></tbody></table><p>+ In at least one region the resistance rate is &gt; 50 %.</p><p># In Intensive Care Units the resistance rate is &lt; 10 %.</p><p>% Extended Spectrum Beta-Lactamase (ESBL) producing strains are always resistant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>Cefotaxime is for parenteral application. Mean peak concentrations 5 minutes after intravenous administration are about 81 &ndash; 102 mg/L following a 1000 mg dose of cefotaxime and about 167 &ndash; 214 mg/L 8 minutes after a 2000 mg dose. Intramuscular injection produces mean peak plasma concentrations of 20 mg/L within 30 minutes following a 1000 mg dose.</p><p><strong>Distribution</strong></p><p>Cefotaxime has good penetration into different compartments. Therapeutic drug levels exceeding the minimum inhibitory levels for common pathogens can rapidly be achieved. Cerebrospinal fluid concentrations are low when the meninges are not inflamed but cefotaxime usually passes the bloodbrain barrier in levels above the MIC of the sensitive pathogens when the meninges are inflamed (3- 30 &mu;g /ml).</p><p>Cefotaxime concentrations (0.2 &ndash; 5.4 &mu;g /ml), inhibitory for most gramnegative bacteria, are attained in purulent sputum, bronchial secretions and pleural fluid after doses of 1000 or 2000 mg. Concentrations likely to be effective against most sensitive organisms are similarly attained in female reproductive organs, otitis media effusions, prostatic tissue, interstitial fluid, peritoneal fluid and gall bladder wall, after therapeutic doses. High concentrations of cefotaxime and O-desacetyl-cefotaxime are achieved in bile.</p><p>Cefotaxime passes the placenta and attains high concentrations in foetal fluid and tissues (up to 6 mg/kg). Small amounts of cefotaxime diffuse into the breast milk. Protein binding for cefotaxime is approximately 25 &ndash; 40%.</p><p>The apparent distribution volume for cefotaxime is 21-37 l after 1000 mg intravenous infusion over 30 minutes</p><p><strong>Biotransformation</strong></p><p>Cefotaxime is partly metabolised in humans. Approximately 15-25% of a parenteral dose are metabolised to the O-desacetyl-cefotaxime metabolite, which also has antibiotic properties.</p><p><strong>Elimination</strong></p><p>The main route of excretion of cefotaxime and O-desacetyl-cefotaxime is through the kidneys. Only a small amount (2%) of cefotaxime is excreted in the bile. In the urine collected within 6 hours 40 &ndash; 60% of the administered dose of cefotaxime is recovered as unchanged cefotaxime and 20% is found as Odesacetylcefotaxime.</p><p>After administration of radioactive labelled cefotaxime more than 80% can be recovered in the urine; 50 &ndash; 60% of this fraction is unchanged cefotaxime and the rest contains metabolites.</p><p>The total clearance of cefotaxime is 240 &ndash; 390 ml/min and the renal clearance is 130 &ndash; 150 ml/min.</p><p>The serum half-lives of cefotaxime and O-desacetyl-cefotaxime are normally about 50 &ndash; 80 and 90 minutes, respectively. In elderly, the serum half-life of cefotaxime is 120 &ndash; 150 min.</p><p>In patients with severely impaired renal function (creatinine clearance 3 &ndash; 10 ml/min) the serum halflife of cefotaxime can be increased to 2.5 &ndash; 3.6 hours.</p><p>There is no accumulation following administration of 1000 mg intravenously.</p><p>In neonates the pharmacokinetics are influenced by gestation and chronological age, the half-life being prolonged in premature and low birth weight neonates of the same age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and toxicity to reproduction. Cefotaxime passes through the placenta. After intravenous administration of 1000 mg cefotaxime during the birth values of 14 &mu;g/ml were measured in the umbilical cord serum in the first 90 minutes after administration, which dropped to approximately 2.5 &mu;g/ml by the end of the second hour after application. In the amniotic fluid, the highest concentration of 6.9 &mu;g/ml was measured after 3 &ndash; 4 hours. This value exceeds the MIC for most gram-negative bacteria.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no other ingredients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aminoglycosides are incompatible with cephalosporins in parenteral mixtures.&nbsp;</p><p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
After reconstitution:
Chemical and physical in-use stability has been demonstrated for 24 hours at 2–8°C after reconstitution with water for injection and 1% lidocaine.
From a microbiological point of view, unless the method of reconstitution precludes the risk of microbial contamination, the product should be used immediately.
If not used immediately, in-use storage times and conditions are the responsibility of user.
After reconstitution and dilution:
Chemical and physical in-use stability for the diluted medicinal product has been demonstrated for 24 hours at 2–8°C.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2–8°C, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg;C.</p><p>Store in the original package in order to protect from light.</p><p>For storage conditions after reconstitution/dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clear glass colorless vials sealed with light grey colour caps.</p><p>Pack size: 1 Vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Intravenous injection</strong></p><p>In case of intravenous administration, reconstitute Totam with water for injection as given in the below table. Shake well until dissolved. The reconstitution time is less than 1 minute.</p><table border="1" cellspacing="0" cellpadding="0" style="width:488px"><tbody><tr><td style="vertical-align:top; width:186px"><p><strong>Intravenous administration</strong></p></td><td style="vertical-align:top; width:131px"><p><strong>Volume of diluent</strong></p></td><td style="vertical-align:top; width:166px"><p><strong>Nature of diluent</strong></p></td></tr><tr><td style="vertical-align:top; width:186px"><p>Totam 1000 mg</p><p>&nbsp;</p></td><td style="vertical-align:top; width:131px"><p>4 ml</p><p>&nbsp;</p></td><td style="vertical-align:top; width:166px"><p>Water for injection</p></td></tr></tbody></table><p><strong>Intramuscular injection</strong></p><p>In case of intramuscular administration, reconstitute Totam with water for injection or 1% lidocaine solution as per the table below. To prevent pain from the injection, a 1% lidocaine solution may be used alternatively (only for adults). Solutions in lidocaine must not be administered intravenously. The product information of the chosen lidocaine containing solution must be regarded.</p><p>When using lidocaine solution as diluent, intravascular injection must be strictly avoided. The 1% lidocaine solution is only to be used for intramuscular injection of the Totam 1000 mg.</p><table border="1" cellspacing="0" cellpadding="0" style="width:485px"><tbody><tr><td style="vertical-align:top; width:188px"><p><strong>Intramuscular administration</strong></p></td><td style="vertical-align:top; width:128px"><p><strong>Volume of diluent</strong></p></td><td style="vertical-align:top; width:163px"><p><strong>Nature of diluent</strong></p></td></tr><tr><td style="vertical-align:top; width:188px"><p>Totam 1000 mg</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:128px"><p>4 ml</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:163px"><p>Water for injection</p><p>or 1% lidocaine solution</p></td></tr></tbody></table><p><strong>Reconstituted solution</strong></p><p>When dissolved in water for injection or 1% lidocaine, a clear, slight yellow to yellow solution is formed.</p><p><strong>Intravenous infusion</strong></p><p>1000 mg of cefotaxime should be dissolved in (40 - 100 ml) of one of the infusion fluids listed below.</p><p><strong>Compatibility with infusion fluids </strong></p><p>Whilst it is preferable to use immediately the prepared solutions for both intravenous and intramuscular injection, Totam is compatible with several commonly used intravenous infusion fluids and will retain satisfactory potency for up to 24 hours refrigerated (2&ndash;8&deg;C) in the following:</p><ul><li>Water for injection</li><li>0.9% Sodium chloride injection</li><li>5% Glucose injection</li><li>5% Glucose and 0.9% sodium chloride injection</li><li>Compound sodium lactate injection (ringer-lactate injection)</li></ul><p>Cefotaxime is also compatible with metronidazole infusion (500 mg/100 ml) and both will maintain potency when refrigerated (2&ndash;8&deg;C) for up to 24 hours.</p><p>The product should be inspected visually for particles. Only clear solution free from particles or precipitates should be used.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10 January 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>